MedTrace Logo

Gastric Cancer Prevention in the Family Members by Helicobacter Pylori Eradication

NCT01678027 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1838

Last updated 2023-11-09

No results posted yet for this study

Summary

This study evaluate whether treatment of Helicobacter pylori infection reduces the incidence of gastric cancer in subjects with family history of gastric cancer.

Conditions

Interventions

DRUG

Placebo

Lansoprazole placebo, amoxicillin placebo, and clarithromycin placebo, all twice a day for 1 week.

DRUG

LAC triple therapy

Lansoprazole 30 mg, amoxicillin 1,000 mg, and clarithromycin 500 mg, all twice a day for 1 week.

Sponsors & Collaborators

  • National Cancer Center, Korea

    lead OTHER_GOV

Principal Investigators

  • Il Ju Choi, M.D., Ph.D. · National Cancer Center, Korea

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-11-30
Primary Completion
2018-12-31
Completion
2035-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01678027 on ClinicalTrials.gov